
Advertise on podcast: Business Of Biotech
This podcast has
333 episodes
Language
EnglishPublisher
Ben ComerExplicit
No
Date created
2023/11/29
Latest episode
2026/11/16
Average duration
54 min.
Release period
8 days
Description
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
Unlock Business Of Biotech podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from Business Of Biotech podcast
Preparing For Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D.
2026/11/16
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated. He also talks through leadership and operating choices for minimizing risk in late-stage development, how FDA's Fast Track and RMAT designations aided communication and CMC planning, and how an outsourced commercial model can help companies prepare for launch and avoid premature fixed costs.
UPDATE (11/18/26): Candel Therapeutics recently became aware that the validation of the IU Assay will cause a six month delay in the completion of the BLA submission for aglatimagene, which is now expected mid-2027.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley
2026/11/09
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matter as much as the molecule itself. He also discusses partnering in China, and the potential for psychedelics in treating psychiatric disorders, including bretisilocin, AbbVie's first psychedelic clinical program.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.
2026/11/02
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Edward (Ned) Patz, M.D., Cofounder and CEO at Grid Therapeutics, explains how a Duke University lab discovery turned into Grid Therapeutics and two clinical-stage cancer immunotherapy programs. Ned talks about discovering the human-derived antibody treatment GT103 and novel Compliment Factor H (CFH) target, the messy realities of funding a new therapeutic approach in cancer, and the leadership lessons that come with running a scrappy virtual biotech.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Bioprinting 3D Human Tissue To Discover And Test New Treatments With Viscient Bio's Keith Murphy
2026/10/26
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Keith Murphy, CEO at Viscient Biosciences, unpacks how 3D human tissue models and scaffold-free bioprinting can change the way developers predict drug safety and model disease. Keith traces his professional journey from MIT and Amgen, to founding Organovo and building Viscient and VivoSim (formerly Organovo) into companies that push New Approach Methodologies (NAM) adoption and smarter, more efficient drug development. Keith also shares policy ideas the FDA could use to further incentivize the use of NAMs.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.
2026/10/19
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and biotech investing. Bret reflects on lessons he learned at Alnylam about the power of genetically validated drug targets and the importance of team culture, why CNS drug development fails so often, and the problem with animal models. He also talks about where AI is truly helping early-stage biotechs, and where it can create problems.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
AI, China, And Biotech Investing With SR One's Simeon George, M.D.
2026/10/12
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets, and the good and bad signs that emerge during diligence. Simeon also discusses a new report published by SR One on how AI and China are changing the strategy and playbook for new drug creation.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding
2026/10/05
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo. Cyriac also discusses China’s newest five-year plan for biotech (2026 to 2030), why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign wealth fund could support preclinical and early-stage drug development leadership at home.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Growing And Scaling A Radiopharmaceuticals Company With AdvanCell's Philina Lee, Ph.D.
2026/09/28
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why radiopharmaceutical companies live or die by manufacturing. Philina talks about AdvanCell's recent oversubscribed $315 million Series D raise, the company's vertically integrated manufacturing capability, and future plans for a regional U.S. manufacturing network. She also reflects on the current targeted alpha therapy landscape and how it could evolve over the next few years.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Finding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D.
2026/09/21
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s. He describes Moonwalk’s adipose-targeted siRNA strategy, the genetics-driven logic behind its targets, and what it takes to fund and build a clinical-stage company. Alex also discusses Moonwalk's recent $70 million Series B raise, using AI to prioritize targets and improve siRNA design, and how weight loss without appetite suppression could preserve lean muscle mass and improve tolerability.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Biotech Finance And Investor Update With Independent Board Director Allan Shaw
2026/09/14
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Independent Board Director and five-time public company CFO Alan Shaw returns to the show for an update on current biotech financing and the strategies needed to secure capital now. Allan explains how biotech investors price risk as the market opens back up, the importance of valuation discipline, and the financing choices that separate “available capital” from “accessible capital.” Allan also discusses the trade-offs inherent to different funding types.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig
2026/09/07
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, David Craig, Cofounder, President, and CEO at Sarcomatrix, explains why the old biotech playbook breaks down in today’s funding environment and what it takes to build a lean virtual drug development company without institutional financing. Craig describes practical financing paths, hard truths about costs, and the tradeoffs that make a rare disease program investable through alternative fundraising strategies. He also shares what can and cannot be outsourced, and how regulatory sequencing shapes financial planning and timelines.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka
2026/08/31
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Olivier Litzka, Partner at Andera Partners, talks about what it really takes for biotech companies to attract capital, stay focused, and survive the moments when biology and execution punch back. Olivia also discusses a collaborative effort in Europe to create a stronger public market and investor base, and what the emergence of AI and Chinese biotech means for building tomorrow's biotech companies.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil
2026/08/24
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Omar Khalil, Managing Director at Santé Ventures, describes forming and funding startups and early-stage biotech companies with a focus on clinical data and differentiation as the key value drivers. Omar talks about his interest in 'undruggable targets,' what's happening with the IPO market, an investor shift from biology risk to commercial risk, and building companies through a venture creation process.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Getting To A First Product Approval With Celcuity's Brian Sullivan
2026/08/17
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Brian Sullivan, CEO at Celcuity, talks about winning the company's first FDA approval for Revtorpyk, a kinase inhibitor for breast cancer patients, and why targeting an “untreated disease mechanism” can beat chasing a single mutation. Brian also discusses the process for licensing a shelved Pfizer asset for development, designing Phase 3 trials that challenge assumptions, the benefits of FDA's Real-Time Oncology Review, and managing downside risk while advancing new indications, all while building a launch-ready company without losing pipeline momentum.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings
2026/08/10
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell therapies for autoimmune disease. Paul is candid about problems with clinical trial infrastructure in the U.S., what it will take to fix trial access (biotechs should actively facilitate patient access to trials and work with community health centers to establish new trial sites), and why biotech leaders have a responsibility to speak up about federal policies shaping the life sciences innovation ecosystem.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Podcast reviews
Read Business Of Biotech podcast reviews
Podcast sponsorship advertising
Start advertising on Business Of Biotech relevant audience podcasts
You may also like to advertise on these Podcasts

4.518808383
American Scandal
Audible

4.689571234
Get Sleepy: Sleep meditation and stories
Slumber Studios

4.79026375
Life is Short with Justin Long
Audible

4.714149353
Bad Friends
Bobby Lee & Andrew Santino

4.7133275
10 to Life
Annie Elise

4.76763467
Criminology
Emash Digital & Mike Ferguson, Mike Morford

4.87554989
The Dr. John Delony Show
Ramsey Network

4.512669676
RedHanded
RedHanded

4.959992000
Legal AF by MeidasTouch
MeidasTouch Network

4.7292862000
The Michael Knowles Show
The Daily Wire